Swiss stocks - Factors to watch on October 12
Swiss stocks - Factors to watch on October 12 ZURICH/GDANSK, Oct 12 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday:
COMPANY STATEMENTS
ROCHE HOLDING AG ROPC.S
Swiss pharmaceutical giant Roche presented on Saturday new Phase III one-year data for vamikibart in uveitic macular edema (UME).
ANALYSTS' VIEWS
ROCHE HOLDING AG ROPC.S - JEFFERIES RAISES TARGET PRICE TO CHF 250 FROM CHF 230
BELIMO HOLDING AG BEAN.S - JEFFERIES RAISES TARGET PRICE TO CHF 1050 FROM CHF 1035
ECONOMY
SNB sight deposits due at 0800 GMT.
(Reporting by Zurich newsroom and Gdansk newsroom)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY, EQUITY/NEWS1, EUR/EQUITY, SWITZERLAND, REUTERS
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey